Abstract:DISEASE OVERVIEW: Chronic lymphocytic leukemia (CLL) is the commonest leukemia in western countries. The disease typically occurs in elderly patients and has a highly variable clinical course. Leukemic transformation is initiated by specific genomic alterations that impair apoptosis of clonal B-cells.DIAGNOSIS: The diagnosis is established by blood counts, blood smears, and immunophenotyping of circulating B-lymphocytes, which identify a clonal B-cell population carrying the CD5 antigen, as well as typical B-cell markers.PROGNOSIS: The two similar clinical staging systems, Rai and Binet, create prognostic information by using results of physical examination and blood counts. Various biological and genetic markers also have prognostic value. Deletions of the short arm of chromosome 17 (del [17p]) and/or mutations of the TP53 gene, predict resistance to chemoimmunotherapy and a shorter time to progression, with most targeted therapies. A comprehensive, international prognostic score (CLL-IPI) integrates genetic, biological and clinical variables to identify distinct risk groups of CLL patients.THERAPY: Only patients with active or symptomatic disease, or with advanced Binet or Rai stages require therapy. When treatment is indicated, several options exist for most CLL patients: a combination of venetoclax with obinutuzumab, ibrutinib monotherapy, or chemoimmunotherapy. For physically fit patients younger than 65 (in particular when presenting with a mutated IGVH gene), chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab remains a standard therapy, since it may have curative potential. At relapse, the initial treatment may be repeated, if the treatment-free interval exceeds 3 years. If the disease relapses earlier, therapy should be changed using an alternative regimen. Patients with a del (17p) or TP53 mutation are a different, high-risk category and should be treated with targeted agents. An allogeneic SCT may be considered in relapsing patients with TP53 mutations or del (17p), or patients that are refractory to inhibitor therapy.FUTURE CHALLENGES: Targeted agents (ibrutinib, idelalisib, venetoclax, obinutuzumab) will be increasingly used in combination to allow for short, but potentially definitive therapies of CLL. It remains to be proven that they generate a superior outcome when compared to monotherapies with inhibitors of Bruton tyrosine kinase, which can also yield long-lasting remissions. Moreover, the optimal sequencing of drug combinations is unknown. Therefore, CLL patients should be treated in clinical trials whenever possible.

New Therapeutic Strategy of Fludarabine-Resistant Relapsed and Refractory Chronic Lymphocytic Leukemia

How I treat refractory and relapsed acute myeloid leukemia

Effect of fludarabine on treatment of patients with chronic lymphocytic leukemia and its influence on survival rate

Fludarabine combined with colony-stimulating factor and cytarabine regimen for treatment of refractory or relapsed acute myeloid leukemia

Efficacy and Safety Evaluation of Fludarabine-Based Chemotherapy Regimen for Patients with Non-Hodgkin Lymphoma A Meta-Analysis

The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma

Current Approaches and Novel New Agents in the Treatment of Chronic Lymphocytic Leukemia

Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia

A Fludarabine-Based Non-Myeloablative Conditioning Regimen in Allogeneic Stem Cell Transplantation from Related and Unrelated Donors in Chronic Myeloid Leukemia.

[Efficacy of Chemoimmunotherapy with Fludarabine, Cyclophosphamide and Rituximab for Chronic Lymphocytic Leukemia].

Advances in Targeted Drugs for Follicular Lymphoma

Research progress on pharmacokinetics of fludarabine and its synergistic effect with cytarabine

Optimization of Donor Lymphocyte Infusion for AML Relapse After Allo-HCT in the Era of New Drugs and Cell Engineering

Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options

Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma

Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment

Efficacy and safety of fludarabine-based combination chemotherapy in patients with previously untreated follicular non-Hodgkin's lymphoma

Allogeneic hematopoietic stem cell transplantation for chronic lymphocytic leukemia

Treating Relapsed/Refractory Acute Myeloid Leukemia with Chidamide, Fludarabine, Cytarabine and Granulocyte-Colony Stimulating Factor with Subsequent Bridging to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation

Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges

Update on the management of relapsed/refractory chronic lymphocytic leukemia